Business

Top News

GSK's Andrew Witty talks strategy
Witty defends himself, GSK: 'Look at what we're able to achive'

Having been fined nearly $500 million in China for bribery, facing investigations in other countries and battling lagging revenue, GSK now faces more cost cuts and is contemplating a stock offering for its ViiV Healthcare. But GSK's CEO Andrew Witty defended himself and his strategy in discussing the drug giant's most recent quarterly earnings report on Wednesday. "Look at what we're able to achieve," he says.

Related Stories

Other Stories